| Dr Sage Kinney Copeland, MD, FACS | |
|
1218 13th Ave Se, Decatur, AL 35601-4307 | |
| (256) 355-6200 | |
| (256) 355-6241 |
| Full Name | Dr Sage Kinney Copeland |
|---|---|
| Gender | Male |
| Speciality | |
| Experience | Years |
| Location | 1218 13th Ave Se, Decatur, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265413124 | NPI | - | NPPES |
| 000019326 | Medicaid | AL | |
| 040011769 | Other | AL | RAILROAD MEDICARE |
| 510-19326 | Other | AL | BCBS |
| 051019326 | Other | AL | PROVIDER NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 00011018 (Alabama) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sage Kinney Copeland, MD, FACS 1218 13th Ave Se, Decatur, AL 35601-4307 Ph: (256) 355-6200 | Dr Sage Kinney Copeland, MD, FACS 1218 13th Ave Se, Decatur, AL 35601-4307 Ph: (256) 355-6200 |
News Archive
In a rigorous medRxiv* preprint paper, a group of researchers demonstrate shifts in age structure and clinical characteristics of individuals affected with coronavirus disease (COVID-19) after social and economic reopening in three US states and show how elderly individuals were less able to reduce contacts when compared to the younger ones.
Amanda Glassman, director of global health policy and a senior fellow at the Center for Global Development (CGD), and Kate McQueston, a program coordinator at CGD, write in the center's "Global Health Policy" blog that a reduction in AIDS funding to Ethiopia from PEPFAR and the Global Fund to Fight AIDS, Tuberculosis and Malaria "might be warranted due to epidemiological trends and improved efficiency, or might cripple progress as health programs dependent on external donors are cut back."
Adding a drug called neostigmine to epidural analgesia during labor can reduce the amount of anesthetic drug required, while avoiding potential complications caused by morphine-like "opioid" drugs, according to a study in the August issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
Portola Pharmaceuticals and Merck today announced the results of EXPLORE-Xa, a Phase 2 exploratory, dose finding study of betrixaban, an investigational oral direct Factor Xa inhibitor. Results showed that a once-daily dose of oral betrixaban, given to patients with non-valvular atrial fibrillation or atrial flutter and at least one risk factor for stroke, reduced the incidence of major and clinically relevant non-major (CRNM) bleeds compared to dose-adjusted warfarin.
An analysis of three previous studies of children and young adults with attention-deficit hyperactivity disorder quantifies for the first time the extent to which stimulant treatment reduces the development of mood disorders, school problems, conduct disorders, substance use disorders and other problems.
› Verified 6 days ago
Dr. George H Godwin Iii, M.D., F.A.C.S. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1218 13th Ave Se, Decatur, AL 35601 Phone: 256-355-6200 Fax: 256-355-6241 | |
Dr. Benjamin W Light, M.D., F.A.C.S. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1218 13th Ave Se, Decatur, AL 35601 Phone: 256-355-6200 Fax: 256-355-6241 |